Applied DNA Sciences Inc (APDN)

[hock1]

houtheman... the company is moving slowly and deliberately and prefers large marketing partnerships like the one they have with Louis Dreyfus.

Bingo! Sorry we did not get a chance to meet at the ASM. I appreciate the work you put into reporting to this board on the ASM. As a result of talking with Jim and others at the meeting (and follow-ups afterward), I believe the Company will employ this very same methodology (i.e., a marketing partnership) in the pharmaceutical vertical. IMO, they will do a deal with a drug distribution company like a Cardinal Health, who will then do deals with the Pharma companies.

In view of the above, your depiction of a one-man marketing entity for Pharma (i.e., Miglano), knocking on Pharma doors is too pessimistic and, I believe, inaccurate. Every major pharma company is already aware of APDN and its marking technology. The biggest impediment to uptake in the pharma industry is the lack of urgency in the industry to adopt dosage marking, thanks to a 2023 deadline in the U.S. to implement dosage marking. The good news is that this same deadline is July, 2016 (next month) in Japan and (don't hold me to this, but I believe) 2018-19 in EU. I think the U.S. will be pressured to move the date up a few years. AIMO

Thanks again for your insights.